Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.
Javier Sánchez RamírezYanelys Morera DíazMónica Bequet-RomeroFrancisco Hernández-BernalYenima Martín BautaKatty-Hind Selman-Housein BernalAna Victoria de la Torre SantosMariela Pérez de la IglesiaLian Trimiño Lorenzonull nullMarta Ayala AvilaPublished in: BMC immunology (2020)
The CIGB-247 CUP has demonstrated that immunization and follow-up of a variety of cancer patients, under day-to-day clinical practice conditions in several Cuban medical institutions, replicate our previous findings in clinical trials: CIGB-247 is safe and immunogenic.